Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06094738 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects
A Phase 1 study, sponsored by Corcept Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT06094738 is a Phase 1 study that has completed, run by Corcept Therapeutics. The registered enrollment target is 30 participants.
The verdict
NCT06094738, a Phase 1 study, has completed, sponsored by Corcept Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The primary objective of the study is to evaluate the effects of a high-fat meal and of a low-fat meal on the bioavailability of relacorilant in healthy subjects.
Interventions
- DRUG Relacorilant under fasted conditions
- DRUG Relacorilant after a high-fat meal
- DRUG Relacorilant after a low-fat meal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-09-19 |
| Est. Completion | 2020-11-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06094738
The ClinicalTrials.gov registry entry for NCT06094738 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corcept Therapeutics, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Relacorilant under fasted conditions is the first listed.
NCT06094738 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06094738 about?
NCT06094738 is a clinical study titled "A Study to Evaluate the Effect of Food on the Oral Bioavailability of Relacorilant in Healthy Subjects". The primary objective of the study is to evaluate the effects of a high-fat meal and of a low-fat meal on the bioavailability of relacorilant in healthy subjects.
What is the current status of trial NCT06094738?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2020-09-19. Estimated completion is 2020-11-16.
What interventions are being tested in trial NCT06094738?
The interventions under investigation include: Relacorilant under fasted conditions (DRUG), Relacorilant after a high-fat meal (DRUG), Relacorilant after a low-fat meal (DRUG).
Who is sponsoring clinical trial NCT06094738?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.